Oncternal Therapeutics Inc. (ONCT) Misses Q4 EPS by 295c

Oncternal Therapeutics Inc. (NASDAQ: ONCT) reported Q4 EPS of ($3.11), $2.95 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $297 thousand versus the consensus estimate of $175 thousand.

For earnings history and earnings-related data on Oncternal Therapeutics Inc. (ONCT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c